LIMK1 and cancer: Results revealed that the upregulation of LIMK1 or CDK5 shared similar activated/inhibited signaling pathways including focal adhesion, ECM‐receptor interaction, cell cycle, and some critical signaling pathways in cancer (Figure 3C).